Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1593906

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1593906

Lysosomal Storage Diseases Market by Disease Type (Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis), Type of Therapy (Enzyme Replacement Therapy, Stem Cell Therapy, Substrate Reduction Therapy), End User - Global Forecast 2025-2030

PUBLISHED:
PAGES: 189 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Lysosomal Storage Diseases Market was valued at USD 9.31 billion in 2023, expected to reach USD 9.98 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 15.43 billion by 2030.

Lysosomal Storage Diseases (LSDs) are a group of rare metabolic disorders characterized by an enzyme deficiency, leading to the accumulation of undigested macromolecules in lysosomes. Given the severe nature of these diseases and their impact on patient quality of life, there is a pressing necessity for enhanced diagnostics, treatments, and therapeutic delivery methods. The primary application revolves around enzyme replacement therapy (ERT), substrate reduction therapy, and gene therapy. End-users range from specialized healthcare facilities to research institutions dedicated to orphan diseases. The market growth is driven by increasing awareness, rising healthcare spending in rare diseases, and advancements in genomic research. Key influencers include growing investments in biotechnology and favorable government policy frameworks supporting orphan drug development. Opportunities lie in leveraging CRISPR and other gene-editing technologies to pioneer novel treatment approaches for LSDs. Additionally, collaborations between pharmaceutical companies and research institutions can accelerate innovation. However, limitations persist due to the high cost of treatment, stringent regulatory barriers, and the limited patient pool, which might deter large-scale investments. Financial sustainability, affordability, and accessibility of therapies remain challenging. Innovating in drug delivery systems and integrating artificial intelligence for personalized medicine are promising avenues to enhance treatment efficacy and patient outcomes. Market insights suggest that niche technological advancements, strategic partnerships, and investment in R&D are critical for capturing emerging opportunities. Although the market is primarily defined by established treatments, there is a pivot towards next-gen therapies involving gene and personalized medicine. Stakeholders should focus on collaborative approaches and patient-centric solutions to navigate the complex landscape, aiming for sustainable growth. By fostering innovation and enhancing global awareness, the industry can address existing limitations and propel significant market expansion in the nascent but evolving field of lysosomal storage diseases.

KEY MARKET STATISTICS
Base Year [2023] USD 9.31 billion
Estimated Year [2024] USD 9.98 billion
Forecast Year [2030] USD 15.43 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lysosomal Storage Diseases Market

The Lysosomal Storage Diseases Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of lysosomal storage disorders worldwide
    • Inclination toward early diagnosis and treatment of diseases
    • Increasing use of enzyme replacement therapies
  • Market Restraints
    • High cost associated with the treatment of t lysosomal storage disease
  • Market Opportunities
    • Advancements in gene editing technologies and gene therapies
    • Emergence of personalized medicine approach to treat lysosomal storage conditions
  • Market Challenges
    • Stringent regulatory framework for approval of lysosomal storage drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lysosomal Storage Diseases Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lysosomal Storage Diseases Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lysosomal Storage Diseases Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lysosomal Storage Diseases Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lysosomal Storage Diseases Market

A detailed market share analysis in the Lysosomal Storage Diseases Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lysosomal Storage Diseases Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lysosomal Storage Diseases Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lysosomal Storage Diseases Market

A strategic analysis of the Lysosomal Storage Diseases Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lysosomal Storage Diseases Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Alexion Pharmaceuticals, Inc., Amicus Therapeutics, ArmaGen, Inc., BioMarin, CHIESI USA, Inc., Denali Therapeutics Inc., Freeline Therapeutics, Homology Medicines, Inc., Horizon Pharma PLC, Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co., Ltd., Lysogene, Neurogene Inc., Novartis AG, Orchard Therapeutics Limited, Pfizer Inc., Protalix, Sangamo Therapeutics, Inc., Sanofi S.A., Spark Therapeutics, Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceutical Company Limited, and Ultragenyx Pharmaceutical Inc..

Market Segmentation & Coverage

This research report categorizes the Lysosomal Storage Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Fabry Diseases, Gaucher's Diseases, Mucopolysaccharidosis, and Pompe's Syndrome.
  • Based on Type of Therapy, market is studied across Enzyme Replacement Therapy, Stem Cell Therapy, and Substrate Reduction Therapy.
  • Based on End User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-DD0700E81E5B

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of lysosomal storage disorders worldwide
      • 5.1.1.2. Inclination toward early diagnosis and treatment of diseases
      • 5.1.1.3. Increasing use of enzyme replacement therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment of t lysosomal storage disease
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in gene editing technologies and gene therapies
      • 5.1.3.2. Emergence of personalized medicine approach to treat lysosomal storage conditions
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory framework for approval of lysosomal storage drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Lysosomal Storage Diseases Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Fabry Diseases
  • 6.3. Gaucher's Diseases
  • 6.4. Mucopolysaccharidosis
  • 6.5. Pompe's Syndrome

7. Lysosomal Storage Diseases Market, by Type of Therapy

  • 7.1. Introduction
  • 7.2. Enzyme Replacement Therapy
  • 7.3. Stem Cell Therapy
  • 7.4. Substrate Reduction Therapy

8. Lysosomal Storage Diseases Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Hospitals

9. Americas Lysosomal Storage Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Lysosomal Storage Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Lysosomal Storage Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Alexion Pharmaceuticals, Inc.
  • 3. Amicus Therapeutics
  • 4. ArmaGen, Inc.
  • 5. BioMarin
  • 6. CHIESI USA, Inc.
  • 7. Denali Therapeutics Inc.
  • 8. Freeline Therapeutics
  • 9. Homology Medicines, Inc.
  • 10. Horizon Pharma PLC
  • 11. Idorsia Pharmaceuticals Ltd.
  • 12. JCR Pharmaceuticals Co., Ltd.
  • 13. Lysogene
  • 14. Neurogene Inc.
  • 15. Novartis AG
  • 16. Orchard Therapeutics Limited
  • 17. Pfizer Inc.
  • 18. Protalix
  • 19. Sangamo Therapeutics, Inc.
  • 20. Sanofi S.A.
  • 21. Spark Therapeutics, Inc.
  • 22. Swedish Orphan Biovitrum AB
  • 23. Takeda Pharmaceutical Company Limited
  • 24. Ultragenyx Pharmaceutical Inc.
Product Code: MRR-DD0700E81E5B

LIST OF FIGURES

  • FIGURE 1. LYSOSOMAL STORAGE DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. LYSOSOMAL STORAGE DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. LYSOSOMAL STORAGE DISEASES MARKET DYNAMICS
  • TABLE 7. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY FABRY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY GAUCHER'S DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY MUCOPOLYSACCHARIDOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY POMPE'S SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY SUBSTRATE REDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM LYSOSOMAL STORAGE DISEASES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. LYSOSOMAL STORAGE DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. LYSOSOMAL STORAGE DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!